LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to stop head and neck cancer from returning
Disease control Recruiting nowThis phase II trial is testing whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery can improve outcomes for patients with PD-L1 positive head and neck cancer that has come back. About 180 participants will receive either carboplatin and paclitaxel, …
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC
-
Biomarker-Guided combo aims to outsmart tough cancers
Disease control Recruiting nowThis phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Blood pressure drug joins forces with immunotherapy and radiation to fight head and neck cancer
Disease control Recruiting nowThis early-phase trial tests whether adding a common blood pressure medication (losartan) to immunotherapy (pembrolizumab) and precise radiation (SBRT) is safe and effective for people with head and neck cancer that has returned, not responded to treatment, or spread to a few oth…
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo attack on stubborn head and neck cancers enters early human testing
Disease control Recruiting nowThis early-phase trial is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to radiation therapy before and during surgery can help treat head and neck cancers that have persisted or come back. About 45 adults with resectable tumors will receive the combinati…
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC